Bodal Chemicals Investor Presentation - November 2025
Bodal Chemicals' investor presentation for November 2025 reports a revenue of ₹9,586 million, up 12% YoY, and an EBITDA of ₹946 million, up 27% YoY for H1FY26. The Benzene downstream products unit has commenced normal production.
The investor presentation provides information on the company's performance and future outlook, which can have a moderate impact on investor sentiment and stock price.
The announcement is an investor presentation, providing a factual overview of the company's financial performance and business highlights. Therefore, a neutral sentiment is appropriate.
* Investor Presentation for November 2025 is enclosed. * H1FY26 Consolidated Revenue: ₹9,586 million, up 12% YoY. * H1FY26 EBITDA: ₹946 million, up 27% YoY. * Dye intermediates revenue grew by 2%, Dyestuff de-grew by 2% and Basic Chemicals grew by 76% YoY during H1FY26. * Chlor Alkali business reported revenue of ₹1,682 million in H1FY26, up 9% YoY. * Subsidiaries (Sener Boya, Chinese, BCTPL, and Indonesian) performed satisfactorily with positive earnings during Q2FY26. * Benzene downstream products unit in Saykha started normal production; expecting gradual growth. * Q2 FY26 Consolidated Revenue from Operations: ₹4,804.5 million. * Q2 FY26 Profit After Tax: ₹59.9 million. * H1 FY26 Consolidated Revenue from Operations: ₹9,346.6 million. * H1 FY26 Profit After Tax: ₹155.3 million.
What to do with a filing like this
Bodal Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bodal Chemicals Limited. Read the original for the full detail.